Beirut, Lebanon (PRWEB) June 20, 2011
Amni BioScience, SAL (“AMNI”) announced today the formal signing of a long-term agreement with Clinique Du Levant Société Médicale SAL (“LEVANT”) in Beirut, Lebanon. This agreement will initiate a wide array of therapies involving the use of adult stem cell products as manufactured by Stemedica Cell Technologies under FDA (United States Federal Drug Administration) approval.
In order to maximize the rapidly expanding research and clinical application opportunities available within the fields of restorative and regenerative medicine, AMNI and LEVANT plan on playing a critical role in the full evolution of the most advanced regenerative-based therapies and services. “We’re honored to be working with a facility with the kind of outstanding leadership as LEVANT”, said Amni BioScience President Mr. Sam Alkhass. “Together, we plan on becoming a world leader in the fields of restorative and regenerative medicine.”
The agreement between AMNI and LEVANT calls for the pro-active implementation of clinical trials using allogeneic adult stem cells as manufactured by Stemedica Cell Technologies, Inc., San Diego, California (“STEMEDICA”) as well as their wholly-owned, Swiss-based subsidiary, Stemedica International. Stemedica is licensed to manufacture allogeneic adult stem cells under cGMP manufacturing practices and is regarded as a world leader in the development and manufacture of allogeneic adult stem cells. “We’re excited about the relationship that our exclusive Middle East Distributor, Amni, has agreed to with LEVANT”, said Dr. Nikolai Tankovich, Chairman of Stemedica International and President, Chief Medical Officer of Stemedica International’s parent firm, Stemedica Cell Technologies, Inc. “We look forward to developing a long and mutually-beneficial working relationship between Stemedica International, which services our Middle East operations, and partnership with LEVANT.”
Stemedica’s product line will be imported into Lebanon by Benta Pharmaceutical, (“BENTA”) the Nation’s leading Pharmaceutical Manufacturing Company. “We’re pleased to be joining Amni BioScience and Stemedica as we work together to bring the regenerative powers of allogeneic adult stem cells to Lebanon and the Middle East”, said Mr. Bernard Tannoury, Chairman of Benta. “Together we will bring the safest and most clinically advanced allogeneic adult stem cells to the region for the betterment of patients and the economy alike.”
Once all importation requirements have been met, Amni BioScience will work closely with the medial leadership of LEVANT to implement a “Clinical Trial to Commercial Pathway” strategy for one or more medical indications. According to AMNI’s Chief Medical Officer, Dr. Jean Pierre SAAB, “We’re working closely with the Ministry of Health in Lebanon, Scientific Societies and Lebanese Order of Physicians, to establish regulatory guidelines that protect patients and create the highest levels of safety and efficacy. We’re committed to helping establish “The Gold Standard” in safety and clinical trial advancements of stem cells here in Lebanon and throughout the Middle East.”
Clinique Du Levant Société Médicale SAL is regarded as one of the most prestigious medical facilities in the Middle East and is recognized for its advanced medical treatment in numerous medical categories. “We’re delighted to be working with Amni BioScience leadership and look forward to building our relationship and service offerings into the regional leader for restorative and regenerative health care. We believe our relationship with the stem cell movement is an excellent addition to the many advanced and basic medical offerings of our facility”, said Dr.Antoine Maalouf, Chairman of LEVANT.
About Amni BioScience SAL
Our vision is to build Amni into a medical powerhouse in the region through the promotion of the most advanced medical services and technologies available in the Middle East. We are bringing this vision into reality through a comprehensive series of representation, ownership and acquisition positions with a select number of targeted corporate partners and properties.
About Clinique Du Levant Société Médicale SAL
The mission of Clinique Du Levant Société Médicale is to provide the highest quality of care and service for all people, while preserving quality of life, by attracting and supporting physicians of the highest character and greatest skill. LEVANT provides world class medical care, continual education, through highly specialized physicians, and dedicated staff. LEVANT is located in Beirut, Lebanon.
About Stemedica and Stemedica International
Stemedica Cell Technologies is a world leader in the manufacture of allogeneic adults stem cells. The company’s headquarters and primary manufacturing facility is located in San Diego, California. Based in Lausanne, Switzerland, Stemedica International is a wholly-owned subsidiary of Stemedica Cell Technologies, Inc. Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for preclinical and human clinical trials. Stemedica is headquartered in San Diego, California.